EUVIMEDObjevte EUVIMED
Open access · CC BY-NC 4.0

Safety and Tolerability of SGLT‐2 Inhibitors Following Lung Transplantation

Peter Wilcox iD, Krysta Walter iD, Jonathan Troost, Elizabeth Belloli

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70104 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Peter Wilcox and 3 co-authors. Institution: Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. Major MEDLINE topics: Sodium-Glucose Transporter 2 Inhibitors, Lung Transplantation, Diabetes Mellitus, Type 2, Graft Rejection. 13 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NCATS NIH HHS, National Center for Advancing Translational Sciences.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i's) are frequently prescribed for T2DM control, with additional efficacy in congestive heart failure therapy and preserving renal function in CKD. Despite their potential to mitigate comorbidities, prescribing of SGLT2i's following solid organ transplantation has been limited due to safety concerns regarding infection, renal function, and diabetic ketoacidosis. SGLT2i prescription following transplantation of other solid organs has been evaluated, but only one study included a limited number of lung transplant recipients. We performed a retrospective case control study of all patients in Michigan Medicine clinics with a prior lung transplant who were prescribed an SGLT2i between January, 2010 and March, 2023. We collected demographic information, medical history pertaining to transplant, SGLT2i prescription history, and abstracted safety, tolerability, and efficacy outcomes for comparison between the SGLT2i cohort and a control population. Among 20 patients who met inclusion criteria, median SGLT2i prescription duration was 372 days. There were no UTI's or GU infections, and severe AKI occurred in five patients. There was a median reduction of 0.6% in hemoglobin A1c within the SGLT2i group not observed in controls ( p = 0.09). Our findings demonstrate safety and tolerability of SGLT2i's following lung transplantation and suggest efficacy in controlling T2DM or PTDM.

Subjects

MeSH terms (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsLung TransplantationDiabetes Mellitus, Type 2Graft RejectionPostoperative ComplicationsHumansMaleFemaleRetrospective StudiesMiddle AgedCase-Control StudiesFollow-Up StudiesPrognosisRisk FactorsGlomerular Filtration RateGraft SurvivalAdultAged

Author keywords

PTDMSGLT‐2SGLT‐2 inhibitorlung transplantlung transplantation

Substances

Sodium-Glucose Transporter 2 Inhibitors

Authors and institutions

  • Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Pharmacy Department, University of Michigan, Ann Arbor, Michigan, USA.
  • Michigan Institute for Clinical Health Research, University of Michigan, Ann Arbor, Michigan, USA.
  • Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA.

ORCID profiles: Peter Wilcox, Krysta Walter

Funding

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences

Cite

APA

Wilcox, P., Walter, K., Troost, J., & Belloli, E. (2025). Safety and Tolerability of SGLT‐2 Inhibitors Following Lung Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70104

Vancouver

Wilcox P, Walter K, Troost J, Belloli E. Safety and Tolerability of SGLT‐2 Inhibitors Following Lung Transplantation. Clinical Transplantation. 2025. doi:10.1111/ctr.70104

BibTeX
@article{Wilcox2025,
  author = {Wilcox, Peter and Walter, Krysta and Troost, Jonathan and Belloli, Elizabeth},
  title = {Safety and Tolerability of SGLT‐2 Inhibitors Following Lung Transplantation},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70104}
}
Start for free →